Better Patient Outcomes.

Better Safety Profiles.

Innovative Pipeline

We are developing a portfolio of internally discovered next generation innovative therapies using integrated chemical genomics-driven approaches and proprietary chemistries for diseases with unmet needs.

We have multiple products in our pipeline at various stages of development for chronic conditions in large therapeutic areas.

Program

  • Brilaroxazine
    Serotonin / dopamine modulator (NCE)
  • RP1208
    Triple reuptake inhibitor (NCE)

Indication

  • Schizophrenia*
  • Bipolar Disorder
  • Major Depressive Disorder
  • ADHD
  • Pulmonary Arterial Hypertension
  • Idiopathic Pulmonary Fibrosis
  • Depression
  • Obesity
  • Discovery
  • Preclinical
  • Phase I
  • Phase II
  • Phase III
  • Schizophrenia
  • Bipolar Disorder
  • Major Depressive Disorder
  • ADHD
  • Pulmonary Arterial Hypertension
  • Idiopathic Pulmonary Fibrosis
  • Depression
  • Obesity
*Ongoing. In January 2022, we began a pivotal Phase 3 study in acute schizophrenia and a long-term safety study in stable schizophrenia patients.

Clinical
Trials

Learn more about our completed and ongoing clinical trials.

Learn More